MR. SPEAKER:

The Committee on Health and Human Services recommends HB 2614 be amended on page 2, following line 9, by inserting:

"(e) "Biological product" means a virus, a therapeutic serum, a toxin, an antitoxin, a vaccine, blood, a blood polypeptide, or an analogous product, arsphenamine or derivative or arphenamine, or any other trivalent organic arsenic compound which is applicable to the prevention, treatment or cure of a disease or condition of humans."

Also on page 2, in line 22, by striking all after "means"; in line 23, by striking "manufacturer" and inserting "any person"; also in line 23, by striking "another" and inserting "a"; in line 25, by striking "prescription drug" and inserting "product";

On page 10, in line 9, by striking all after "Product"; by striking all in lines 10 and 11; in line 12, by striking all before the period and inserting "shall have the meaning as defined by part H of the federal drug supply chain security act, 21 U.S.C. § 351 et seq., 21 U.S.C. § 360eee"

On page 11, in line 20, after "product" by inserting "or to whom a manufacturer, repackager, wholesale distributor or dispenser transfers direct ownership of a product"

And by redesignating subsections, paragraphs, subparagraphs and clauses accordingly;

On page 22, in line 41, after "product" by inserting ", excluding a biological product,";

On page 25, in line 32, by striking "shall" and inserting "shall"

And the bill be passed as amended.

_____________________________Chairperson